Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [41] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2− Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Deborah Goldschmidt
    Anand A. Dalal
    Hela Romdhani
    Sneha Kelkar
    Annie Guerin
    Genevieve Gauthier
    Eric Q. Wu
    Polly Niravath
    Tania Small
    Advances in Therapy, 2018, 35 : 482 - 493
  • [42] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [43] Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib
    Emily Nash Smyth
    Julie Beyrer
    Kimberly R. Saverno
    Elizabeth Hadden
    Hamed Abedtash
    Angelo DeLuca
    Garreth W. Lawrence
    Sarah Rybowski
    Drugs - Real World Outcomes, 2022, 9 : 681 - 693
  • [44] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
    Mitra, D.
    Darden, C.
    McSorley, D.
    Davis, K.
    Band, J.
    Iyer, S.
    VALUE IN HEALTH, 2018, 21 : S36 - S36
  • [45] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
    Rugo, Hope S.
    Brufsky, Adam
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Layman, Rachel M.
    Cristofanilli, Massimo
    Torres, Mylin A.
    Curigliano, Giuseppe
    Finn, Richard S.
    DeMichele, Angela
    NPJ BREAST CANCER, 2022, 8 (01)
  • [46] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2-BREAST CANCER IN ARGENTINA
    Novick, D.
    Moneta, M., V
    Fischman, M.
    Zarino, N.
    Gallino, J.
    Carter, Cuyun G.
    Haro, J. M.
    VALUE IN HEALTH, 2020, 23 : S62 - S63
  • [47] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [48] Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer
    Wander, S. A.
    Spring, L. M.
    Stein, C. R.
    Yuen, M.
    Zangardi, M.
    O'Shaughnessy, J.
    Bardia, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [49] Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study
    Mycock, Katie
    Zhan, Lin
    Hart, Kieran
    Taylor-Stokes, Gavin
    Milligan, Gary
    Atkinson, Christian
    Mitra, Debanjali
    FUTURE ONCOLOGY, 2021, 18 (03) : 349 - 362
  • [50] Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer
    Li, Jingping
    Zhang, Xiangmei
    Yang, Chao
    Lv, Yalei
    Yang, Hua
    Kong, Xiangshun
    Han, Meng
    Wang, Zunyi
    Ma, Jie
    Han, Jianjun
    Liu, Yunjiang
    MEDICINE, 2021, 100 (44)
12345